Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Telix Pharmaceuticals ( (AU:TLX) ) just unveiled an announcement.
Telix Pharmaceuticals has corrected an earlier Appendix 2A filing with the ASX, clarifying that 51,828 options (TLXAL) were exercised for cash, resulting in the issuance of 51,828 ordinary shares rather than the 37,295 shares previously disclosed under a cashless exercise provision. The update, lodged on 14 January 2026 and backdating the issue of the shares to 25 November 2025, tidies up an administrative error in the company’s capital management records but does not signal a new transaction, instead ensuring accurate disclosure of Telix’s share count and option exercise mechanics for investors and regulators.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company listed on the ASX under the code TLX. The company operates in the pharmaceuticals and biotechnology sector, with a focus likely on developing and commercialising specialised therapies, as suggested by its use of options and equity-based instruments typical of growth-oriented life sciences firms.
Average Trading Volume: 1,764,484
Technical Sentiment Signal: Sell
Current Market Cap: A$3.81B
Learn more about TLX stock on TipRanks’ Stock Analysis page.